| Cas No.: | 2349386-89-4 |
| 名称: | Uridine, 4-oxime, 5'-(2-methylpropanoate) |
| 别名: | EIDD2801,EIDD 2801 |
| SMILES: | |
| 分子式: | C13H19N3O7 |
| 分子量: | 329.31 |
| 纯度: | |
| 保存条件: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | |
| In Vivo: | |
| In Vitro: | |
| References: | Mechanism of action: EIDD-2801 is hydrolyzed in vivo to N4-hydroxycytidine, which is phosphorylated in tissue to the active 5’-triphosphate form, and incorporated into the genome of new virions, resulting in the accumulation of inactivating mutations, known as viral error catastrophe.A remdesivir resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine. Indication: EIDD-1931 and its prodrug EIDD-2801 is being studied for its activity against a number of viral infections including influenza, MERS-CoV, and SARS-CoV-2. Absorption: EIDD-2801 is orally bioavailable in non-human primates. Metabolism:EIDD-2801 is hydrolyzed to N4-hydroxycytidine, which distributes into tissues.<2> Once inside cells, N4-hydroxycytidine is phosphorylated to the 5'-triphosphate form. |
| Kinase Assay: | |
| Cell Assay: | |
| Animal Administration: | |
| References: |
MSDS
| TITLE | DOWNLOAD |
| MSDS_3161_DC27035_2349386-89-4 |
|
COA
| LOT NO. | DOWNLOAD |
|
|
